Shun Lu, MD, PhD, is a Director of the Oncology Department and Professor at Shanghai Chest Hospital. Dr. Lu serves on the International Affairs Committee of the American Society of Clinical Oncology, and Multidisciplinary Cancer Management Courses Working Group. He is also a member of the State Food and Drug Administration Expert Panel, Commissioner of the Oncology Society Chinese Medical Association, Selected Director of the Chinese Lung Cancer Study Association, and Standing Director & Deputy Secretary of the Chinese Society of Clinical Oncology. Dr. Lu is a member of the International Association for the Study of Lung Cancer, Associate Editor of the Journal of Thoracic Oncology, and serves on the editorial board of The Oncologist.

Yanfei Liu serves as Director of the Clinical Trial Agency Office of the Cancer Hospital of Fudan University, responsible for establishing and improving standard clinical trial institutional management and standard trial project management. Yanfei works to continually strengthen the quality management of clinical research, the training and management of clinical researchers, management of clinical research contracts, management of central clinical research drugs, and clinical research electronic systems. In this capacity, she has helped to manage 48 clinical new drug trials from phases 1 through 4, initiated by both domestic and foreign sponsors, in colorectal cancer, gastric cancer, lymphoma, lung cancer, and breast cancer.

Xiuqin Wang, PhD, is Deputy Chief Physician and Deputy Director of the Science & Technology Department of Jiangsu Provincial People's Hospital, Director of Ethics, and Director of the Operations Office of Jiangsu Provincial Institute of Clinical Medicine. Dr. Wang is Deputy Secretary-General of the China Association of Drug Clinical Trials Institutions; Secretary-General of the Pharmaceutical Clinical Evaluation Research Committee, Jiangsu Pharmaceutical Association; international inspector of the AAHRPP certification site in the US; international inspector of the Asia Pacific Regional Ethics Review Forum; and published Operating Procedures for the Ethics Committee of Clinical Trial Institutions, the first monograph in its field in China.

Hannah started her own business as a consultant after retired from JNJ in Feb. 2019. Hannah has worked for pharmaceutical industry for more than 20 years (GSK: May 1997 ~Sep 2012; JNJ: Sep 2012 ~ Jan 2019), where she developed various expertise including clinical operation: study monitoring, trial management, protocol design, draft clinical study report and training; GCP audit including investigator site, local operating company, external service provider; GCLP and PV audit; clinical Quality Management System training, set up and refinement; Training on Risk-based monitoring etc.

Lin Wang, MD, serves as Head of Takeda Development Center, Asia Vice President, for Takeda China, where she is responsible for all R&D activities across all therapeutic areas in Asia. She previously served as Head of the Asia Biologics Development Unit, Associate Vice President Asia-Pacific R&D HUB, for Sanofi in China, where she also served as Head of Asia Pacific Expansion and Life Cycle Management Department, Associate Vice President Asia Pacific Therapeutic Strategic Unit. Dr. Wang earned her Medical Degree from Peking University Health Science Center (formerly Beijing Medical University), and was a Research Fellow in the Center’s Cancer Hospital/Institute of the Chinese Academy of Science.

Dr. Xu is currently the Executive Vice President and Head of Clinical Development and Regulatory Aff airs at Zai Laboratory. Dr. Xu has 25 years of experience in drug clinical development, and has been the Chairman of the Advisory Council of DIA China and DIA Global Board of Directors from 2011 to 2015. Dr. Xu got his MD from Peking Union Medical Colleague and MBA from the University of Illinois at Chicago.

SVP, Head of Statistics and Data Science, BeOne Medicine; leading R&D data innovation and the development of BeOne Digital Platform, an end-to-end digital clinical trial platform 2013-2017: Senior Director,Head of Statistics, APAC, MSD Ph.D. in Statistics, North Carolina State University Associate Editor for Journal of Biopharmaceutical Statistics and Pharmaceutical Statistics Previous member of DIA Advisory Committee in China

Carol Zhu, RPh, MBA, serves as Senior Vice President and Managing Director for DIA Greater China. She joined DIA from the Bill & Melinda Gates Foundation, where she was the Senior Program Officer for R&D Programs. Prior to her work at the Gates Foundation, she was Founder and Chief Executive Officer of START Shanghai, one of the first phase 1 oncology service companies in China. She also held positions at Merck Sharp & Dohme and GlaxoSmithKline, where she was key to establishing GSK’s R&D Center in Shanghai. Ms. Zhu earned her Masters Degree in Business Administration from Rutgers University and her undergraduate degree in pharmaceutical science from Peking University Health Science Center (Beijing Medical University).